3 results
checkpoint inhibitors ebm honc immune indications nejm nsclc oncology pacific pathophysiology pharmacology targets
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
Durvalumab after ... Honc #PACIFIC #Durvalumab
Immune Checkpoint Inhibitors PD-1 inhibitors - Nivolumab - Pembrolizumab CTLA-4 inhibitors - Ipilimumab - Tremelimumab PD-L1 inhibitors - Atezolizumab
Atezolizumab - Durvalumab
Checkpoint inhibitors and indications Anti CTLA-4 antibody: • Ipilimumab: Malignant melanoma, Renal cell cancer Anti-PD-1 antibody: • Nivolumab:
Breast cancer • Durvalumab
No results found for "Durvalumab"
Try removing search terms or sorting by relevance
Or Upload an image for you and others searching for #Durvalumab